Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.050
-0.020 (-1.87%)
At close: Apr 4, 2025, 4:00 PM
1.089
+0.039 (3.75%)
After-hours: Apr 4, 2025, 7:56 PM EDT

Chemomab Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Net Income
--24.22-27.65-12.48-5.95
Upgrade
Depreciation & Amortization
-0.070.060.030.02
Upgrade
Stock-Based Compensation
-1.493.212.020.13
Upgrade
Change in Accounts Receivable
-0.9-0.06-2.06-0.1
Upgrade
Change in Accounts Payable
--1.170.351.180.07
Upgrade
Change in Other Net Operating Assets
--0.683.72-1.070.59
Upgrade
Operating Cash Flow
--23.61-20.37-12.37-5.24
Upgrade
Capital Expenditures
--0-0.07-0.24-0.04
Upgrade
Sale of Property, Plant & Equipment
---1-
Upgrade
Investment in Securities
-15.8819.6-45.95-0.02
Upgrade
Other Investing Activities
---0-
Upgrade
Investing Cash Flow
-15.8819.53-45.19-0.06
Upgrade
Issuance of Common Stock
-3.50.4158.651.25
Upgrade
Repurchase of Common Stock
---1.22--
Upgrade
Other Financing Activities
---2.43-
Upgrade
Financing Cash Flow
-3.5-0.8161.074.75
Upgrade
Net Cash Flow
--4.23-1.653.51-0.55
Upgrade
Free Cash Flow
--23.61-20.44-12.61-5.28
Upgrade
Free Cash Flow Per Share
--2.01-1.80-1.22-0.77
Upgrade
Cash Income Tax Paid
--0.19-0.35--
Upgrade
Levered Free Cash Flow
--15.49-10.87-6.07-2.56
Upgrade
Unlevered Free Cash Flow
--15.49-10.87-6-2.56
Upgrade
Change in Net Working Capital
2.321.13-3.770.09-1.06
Upgrade
Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q